India Closer To Dengue Vaccine Rollout As Climate Risks Intensify Disease Spread

India may soon have access to its first widely usable dengue vaccine, a development that comes at a critical time as climate change is altering the pattern and spread of mosquito-borne diseases across the country.

An expert panel under the country’s top drug regulator has recommended approval for Takeda’s dengue vaccine, Qdenga, for import into India. The recommendation, however, is conditional upon the company conducting a post-marketing study within six months to assess safety and effectiveness in the Indian population.

If cleared by the regulator, the vaccine is expected to be administered to individuals between 4 and 60 years of age, potentially offering a new layer of protection in a country that witnesses recurring dengue outbreaks, particularly during and after the monsoon season.

The timing of the development is significant. Public health experts have been warning that climate change is contributing to the wider spread of dengue by expanding the habitat of the Aedes mosquito, the primary carrier of the virus. Warmer temperatures, erratic rainfall, and prolonged humid conditions are creating favorable breeding environments, leading to longer transmission seasons and outbreaks in areas that were previously less affected.

Urbanization, water stagnation, and changing weather patterns have further compounded the problem, with cities and peri-urban regions reporting increasing caseloads year after year. Hospitals across several states routinely face pressure during peak dengue seasons, highlighting the need for preventive tools beyond vector control.

India’s dengue control efforts have so far relied largely on mosquito management, early detection, and supportive clinical care. While these measures remain crucial, the absence of a widely deployable vaccine has been seen as a major gap in the country’s public health strategy.

The proposed introduction of Qdenga could help bridge this gap. Unlike earlier vaccines, it does not require prior dengue infection before administration, making it suitable for a broader population in endemic regions.

The recommendation by the expert panel is based on data from global and Indian clinical trials. A large Phase 3 trial involving about 21,000 participants across multiple countries showed the vaccine to be effective, while a separate study conducted in India found it to be safe and capable of generating an immune response in the target age group.

In addition, post-marketing data from countries where the vaccine is already in use did not reveal any new major safety concerns.

The vaccine has already been approved in over 40 countries and has seen millions of doses administered worldwide. Its global rollout has been closely watched by countries like India, where dengue remains endemic.

In India, the vaccine is expected to be marketed in collaboration with Biological E, which is partnering with Takeda to support local supply. The collaboration is also aligned with the government’s push for domestic manufacturing under the “Make in India” initiative, which could help improve accessibility and affordability if approval is granted.

While the recommendation marks a significant regulatory step, experts stress that vaccination alone will not eliminate dengue. Integrated strategies—including vector control, public awareness, improved sanitation, and surveillance—will continue to play a central role.

At the same time, the availability of a vaccine could reduce the severity of outbreaks, lower hospitalizations, and ease the burden on healthcare systems, especially during peak transmission periods.

The global incidence of dengue has risen significantly in the past 50 years, and every projection shows dengue increasing in the next 50.